
Gary S Gilkeson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9205851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human SLE variant <i>NCF1</i> -R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. Annals of the Rheumatic Diseases, 2022, 81, 255-267.	0.9	14
2	<scp>Upâ€Regulated</scp> Interleukinâ€10 Induced by <scp>E2F</scp> Transcription Factor 2– <scp>MicroRNA</scp> â€17â€5p Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 496-507.	5.6	12
3	Safety and Efficacy of Mesenchymal Stromal Cells and Other Cellular Therapeutics in Rheumatic Diseases in 2022: A review of what we know so far. Arthritis and Rheumatology, 2022, , .	5.6	7
4	Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Science and Medicine, 2022, 9, e000704.	2.7	9
5	Expression of GM-CSF Is Regulated by Fli-1 Transcription Factor, a Potential Drug Target. Journal of Immunology, 2021, 206, 59-66.	0.8	14
6	Formal neurocognitive function and anti-N-methyl-D-aspartate receptor antibodies in paediatric lupus. Lupus Science and Medicine, 2021, 8, e000462.	2.7	2
7	Genetic landscape of Gullah African Americans. American Journal of Physical Anthropology, 2021, 175, 905-919.	2.1	9
8	1506â€A human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. , 2021, , .		0
9	Georgia Abortion Law and Our Commitment to Patients. Arthritis and Rheumatology, 2020, 72, 377-378.	5.6	1
10	Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus. Genome Biology, 2020, 21, 281.	8.8	8
11	Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice. PLoS ONE, 2020, 15, e0230499.	2.5	14
12	Treating Systemic Lupus Erythematosus (SLE): The Impact of Historical Environmental Context on Healthcare Perceptions and Decision-Making in Charleston, South Carolina. International Journal of Environmental Research and Public Health, 2020, 17, 2285.	2.6	2
13	Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery in Clinic. Frontiers in Microbiology, 2020, 11, 613268.	3.5	12
14	Gut microbiota differently contributes to intestinal immune phenotype and systemic autoimmune progression in female and male lupus-prone mice. Journal of Autoimmunity, 2020, 108, 102420.	6.5	39
15	Mesenchymal Stem Cells from Chronic Pancreatitis Patients Show Comparable Potency Compared to Cells from Healthy Donors. Stem Cells Translational Medicine, 2019, 8, 418-429.	3.3	8
16	Progesterone decreases gut permeability through upregulating occludin expression in primary human gut tissues and Caco-2 cells. Scientific Reports, 2019, 9, 8367.	3.3	49
17	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Annals of the Rheumatic Diseases, 2019, 78, 1235-1241.	0.9	64
18	154â€Impact of diagnosis age on quality of life among patients with systemic lupus erythematosus. , 2019,		0

, .

GARY S GILKESON

#	Article	IF	CITATIONS
19	70â€R848 (Resiquimod), a TLR 7/8 agonist, accelerates disease and causes a fatal myeloproliferative disorder in NZM 2410 lupus-prone mice. , 2019, , .		0
20	Novel mechanism for estrogen receptor alpha modulation of murine lupus. Journal of Autoimmunity, 2019, 97, 59-69.	6.5	9
21	A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports, 2018, 10, 933-941.	4.8	79
22	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
23	Mouse models of lupus: what they tell us and what they don't. Lupus Science and Medicine, 2018, 5, e000199.	2.7	112
24	Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy. Stem Cells Translational Medicine, 2018, 7, 11-19.	3.3	51
25	An Analytic Approach Using Candidate Gene Selection and Logic Forest to Identify Gene by Environment Interactions (G × E) for Systemic Lupus Erythematosus in African Americans. Genes, 2018, 9, 496.	2.4	7
26	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
27	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. International Journal of Molecular Sciences, 2018, 19, 2331.	4.1	12
28	A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nature Genetics, 2017, 49, 433-437.	21.4	143
29	Combined role of vitamin D status and <i>CYP24A1</i> in the transition to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 153-158.	0.9	40
30	Plasmacytoid dendritic cell distribution and maturation are altered in lupus prone mice prior to the onset of clinical disease. Clinical Immunology, 2017, 175, 109-114.	3.2	12
31	Estrogen decreases tight junction protein ZO-1 expression in human primary gut tissues. Clinical Immunology, 2017, 183, 174-180.	3.2	29
32	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
33	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis and Rheumatology, 2017, 69, 630-642.	5.6	56
34	Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function. Stem Cell Research and Therapy, 2017, 8, 192.	5.5	19
35	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
36	Early Ovariectomy Results in Reduced Numbers of CD11c+/CD11b+ Spleen Cells and Impacts Disease Expression in Murine Lupus. Frontiers in Immunology, 2016, 7, 31.	4.8	25

GARY S GILKESON

#	Article	IF	CITATIONS
37	Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases. Clinical Immunology, 2016, 173, 81-86.	3.2	18
38	Acetylation impacts Fliâ€1â€driven regulation of granulocyte colony stimulating factor. European Journal of Immunology, 2016, 46, 2322-2332.	2.9	18
39	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. Annals of the Rheumatic Diseases, 2016, 75, 2007-2013.	0.9	16
40	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.9	10
41	Complement-Targeted Therapies in Lupus. Current Treatment Options in Rheumatology, 2015, 1, 10-18.	1.4	3
42	A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Science and Medicine, 2015, 2, e000087.	2.7	12
43	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. American Journal of Human Genetics, 2015, 96, 731-739.	6.2	36
44	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	3.2	10
45	Estrogen Receptor α Deficiency Modulates TLR Ligand–Mediated PDC-TREM Expression in Plasmacytoid Dendritic Cells in Lupus-Prone Mice. Journal of Immunology, 2015, 195, 5561-5571.	0.8	11
46	The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
47	Are Microparticles the Missing Link between Thrombosis and Autoimmune Diseases? Involvement in Selected Rheumatologic Diseases. Seminars in Thrombosis and Hemostasis, 2014, 40, 675-681.	2.7	13
48	Pregnancy outcomes among African–American patients with systemic lupus erythematosus compared with controls. Lupus Science and Medicine, 2014, 1, e000020.	2.7	24
49	A9.15â€Higher disease damage among african americans with familial versus sporadic systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, A98-A98.	0.9	0
50	Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus. Journal of Neuroinflammation, 2014, 11, 171.	7.2	13
51	Sex differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE). Journal of Immunotherapy Applications, 2014, 1, 1.	3.0	32
52	Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription. American Journal of Human Genetics, 2014, 94, 586-598.	6.2	59
53	Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clinical Rheumatology, 2014, 33, 1611-1619.	2.2	91
54	Differential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin. Journal of Immunology, 2014, 193, 4381-4390.	0.8	53

GARY S GILKESON

#	Article	IF	CITATIONS
55	Sex Differences in Monocyte Activation in Systemic Lupus Erythematosus (SLE). PLoS ONE, 2014, 9, e114589.	2.5	25
56	Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. Rheumatology International, 2013, 33, 2677-2681.	3.0	31
57	Hematopoetic and mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus — Where are we now?. Clinical Immunology, 2013, 148, 328-334.	3.2	23
58	Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression. PLoS Genetics, 2013, 9, e1003870.	3.5	36
59	Allogenic Mesenchymal Stem Cell Transplantation Ameliorates Nephritis in Lupus Mice via Inhibition of B-Cell Activation. Cell Transplantation, 2013, 22, 2279-2290.	2.5	61
60	Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in Murine Lupus Nephritis. PLoS ONE, 2013, 8, e64650.	2.5	33
61	Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clinical Immunology, 2012, 145, 142-152.	3.2	52
62	Estrogen receptor alpha modulates toll-like receptor signaling in murine lupus. Clinical Immunology, 2012, 144, 1-12.	3.2	44
63	Estrogen Receptors in Immunity and Autoimmunity. Clinical Reviews in Allergy and Immunology, 2011, 40, 66-73.	6.5	232
64	Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2467-2475.	6.7	408
65	Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Annals of the Rheumatic Diseases, 2010, 69, 1423-1429.	0.9	380
66	Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clinical Immunology, 2008, 128, 259-268.	3.2	94
67	Inflammatory modulation of PPARÎ ³ expression and activity. Clinical Immunology, 2006, 118, 276-283.	3.2	19
68	New therapies and preventive strategies to treat and minimize damage in lupus. Current Rheumatology Reports, 2005, 7, 457-462.	4.7	1
69	Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice. Clinical Immunology, 2003, 107, 186-197.	3.2	12
70	Prospective Measure of Serum 3-Nitrotyrosine Levels in Systemic Lupus Erythematosus: Correlation with Disease Activity. Proceedings of the Association of American Physicians, 1999, 111, 611-621.	2.0	77